What is HC Wainwright’s Forecast for Insmed FY2028 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Stock analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of Insmed in a research report issued on Thursday, December 18th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will earn $3.15 per share for the year, down from their prior estimate of $3.42. HC Wainwright currently has a “Buy” rating and a $230.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period last year, the firm earned ($1.27) earnings per share. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. Guggenheim decreased their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday. Evercore ISI reaffirmed an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. Bank of America lifted their price objective on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Royal Bank Of Canada reduced their target price on Insmed from $215.00 to $195.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Wolfe Research set a $167.00 target price on Insmed and gave the stock an “outperform” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $205.41.

Insmed Trading Up 5.0%

Shares of INSM opened at $174.84 on Friday. The business’s 50-day moving average price is $187.66 and its 200 day moving average price is $143.02. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $37.29 billion, a P/E ratio of -28.25 and a beta of 1.01. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75.

Institutional Trading of Insmed

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after purchasing an additional 2,291,328 shares during the last quarter. Norges Bank acquired a new position in shares of Insmed during the 2nd quarter worth about $194,728,000. Adage Capital Partners GP L.L.C. boosted its stake in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership grew its holdings in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd bought a new position in Insmed in the 2nd quarter worth approximately $153,389,000.

Insider Buying and Selling at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the sale, the insider directly owned 36,461 shares of the company’s stock, valued at $7,073,434. This trade represents a 45.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elizabeth M. Anderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $204.58, for a total value of $1,022,900.00. Following the completion of the sale, the director directly owned 58,729 shares of the company’s stock, valued at approximately $12,014,778.82. The trade was a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 157,829 shares of company stock valued at $30,266,463 in the last quarter. Corporate insiders own 3.00% of the company’s stock.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Unusual bullish options activity: traders bought a large block of INSM calls (≈6,582 contracts, +78% vs. average), signaling speculative or hedge interest that can support a bounce after the sell‑off.
• Positive Sentiment: Pipeline add — Insmed announced it is adding a new monoclonal‑antibody asset while reshaping its pipeline, which investors may view as a constructive move to offset the terminated sinus program. INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
• Neutral Sentiment: Analysts trimmed targets but mostly stayed constructive — TD Cowen cut its target to $241 and Guggenheim trimmed to $221 while maintaining buy ratings; these lower targets temper upside but keep institutional support. Benzinga analyst note
• Negative Sentiment: Clinical failure and program termination: a Phase IIb trial in chronic rhinosinusitis showed no benefit, leading Insmed to discontinue development of the drug — the principal trigger for the multi‑day share plunge and elevated volatility. High‑flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri
• Negative Sentiment: Market reaction and commentary: coverage noted a near‑20% drop after hours and broad analyst/media focus on the failure; sell‑side and floor commentary (Mizuho/Barron’s) emphasized the stock’s sharp decline. Insmed Stock Plummets 19%
• Negative Sentiment: Analyst EPS downgrade: HC Wainwright cut FY2028 EPS estimates (now $3.15 from $3.42), signaling reduced near‑term earnings expectations tied to program changes and greater uncertainty.
• Negative Sentiment: Insider sale: CEO William Lewis sold 10,699 shares at an average ~$167 on Dec. 18 (SEC filing), reducing his stake ~3.4% — insider selling often raises investor concern when timed near volatile news. SEC Form 4 — William Lewis sale

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.